BioSpace News Archive

Heritage CARES, a confidential and evidence-based virtual recovery program for substance misuse and suicide prevention and intervention, announces the appointment of its new EVP and Executive Director Rich Jones, MA, MBA, LCAS, SAP.

UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced that it will present at the following virtual conferences in June

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic’s President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industry conference

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021. Apnimed’s presentation is scheduled for Tuesday, June 1 st at 4:30pm ET.

The collaboration will transform how IP-sensitive data is managed and shared across the NCATS’ network

Spacelabs Healthcare (the “Company” or “Spacelabs”), a division of OSI Systems, Inc. (“OSI Systems”) (NASDAQ: OSIS), today announced the release of Lifescreen™ Pro event screening system. Lifescreen Pro expands the Company’s non-invasive cardiology offerings, which include Spacelabs Pathfinder SL ambulatory ECG analysis system.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors.

Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of enrollment for CHAPERONE Phase 3 trial

A new alliance of the American Heart Association’s Precision Medicine Platform with Hitachi Vantara facilitates rapid, accurate scientific data research in health care